Drug Trial Radar · NCT07507500
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8,100
Planned (sponsor's estimate)
Start
Sep 2, 2026
Primary completion
Jul 2029
Study completion Jan 2030
Sponsor
- Lead sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez DíazAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
- First posted
- Apr 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one. After PCI, patients usually receive two antiplatelet medicines for up to 12 months to help prevent another heart attack or stroke, but this treatment can also increase bleeding risk. This study will compare a shorter course of dual antiplatelet therapy followed by one antiplatelet medicine alone versus the standard 12-month course. In addition, the study will compare two commonly used antiplatelet drugs, prasugrel and ticagrelor. The goal is to find out which strategy best prevents death, heart attack, or stroke while minimizing serious bleeding. This study is not testing any new intervention, rather comparing approved drugs and approved durations of use.
Conditions
- Myocardial Infarction (MI)
Interventions
PrasugrelDrug
Prasugrel during 12 months
TicagrelorDrug
Ticagrelor plus aspirin
Primary outcomes
What the sponsor says the trial is designed to measure.
- ischemic eventsTime frame: 12 months
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
Mater Private Network Dublin
Dublin, Ireland · Not yet recruiting
Paula Stradiņa klīniskā universitates slimnīca
Riga, Latvia · Not yet recruiting
Oslo University Hospital, Ullevål.
Oslo, Norway · Not yet recruiting
Saint John Paul II Hospital in Cracow
Krakow, Poland · Not yet recruiting
Fundación Jiménez Díaz University Hospital
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.